Chugai Pharmaceutical (OTCMKTS:CHGCY) Releases Quarterly Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) posted its quarterly earnings results on Friday. The company reported $0.23 earnings per share (EPS) for the quarter, Zacks reports. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%.

Chugai Pharmaceutical Trading Down 0.3%

Chugai Pharmaceutical stock opened at $23.48 on Friday. The firm’s 50 day simple moving average is $22.80 and its 200 day simple moving average is $24.47. The firm has a market capitalization of $77.27 billion, a PE ratio of 29.72 and a beta of 0.64. Chugai Pharmaceutical has a 1-year low of $19.50 and a 1-year high of $31.26.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.